HPTN 083: Incident Infections and Emergent Resistance in MSM and TGW Receiving Cabotegravir Long-Acting PrEP

March 6-10, 2021; Virtual
Longitudinal analysis of HIV infections, viral load, cabotegravir concentrations, and emergent resistance in HPTN 083 demonstrated the importance of prompt diagnosis and initiation of ART to avoid resistance in cases of breakthrough infection with long-acting cabotegravir as PrEP.
Format: Microsoft PowerPoint (.ppt)
File Size: 382 KB
Released: March 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

An expert panel of healthcare professionals and patient advocates discuss barriers faced by aging patients with HIV, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Lydia Mungherera, MBChB Cristina Mussini, MD Dorothy Onyango Melanie Reese Marc Thompson
Released: September 23, 2022

Expert selections of cutting-edge HIV data, including the latest on long-acting therapies and pre-exposure prophylaxis

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Darcy Wooten, MD
Released: September 23, 2022

Expert analysis of barriers and solutions to PrEP uptake in key populations

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: September 23, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP David A. Wohl, MD Released: September 23, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings